A Novel Class of Schistosoma mansoni Histone Deacetylase 8 (HDAC8) Inhibitors Identified by Structure-Based Virtual Screening and In Vitro Testing

A promising means in the search of new small molecules for the treatment of schistosomiasis (amongst other parasitic ailments) is by targeting the parasitic epigenome. In the present study, a docking based virtual screening procedure using the crystal structure of histone deacetylase 8 from Schistos...

Full description

Bibliographic Details
Published in:	Molecules
Main Authors:	Conrad V. Simoben, Dina Robaa, Alokta Chakrabarti, Karin Schmidtkunz, Martin Marek, Julien Lancelot, Srinivasaraghavan Kannan, Jelena Melesina, Tajith B. Shaik, Raymond J. Pierce, Christophe Romier, Manfred Jung, Wolfgang Sippl
Format:	Article
Language:	English
Published:	MDPI AG 2018-03-01
Subjects:	epigenetics crystal structure docking histone deacetylase (HDAC) inhibitors schistosomiasis virtual screening
Online Access:	http://www.mdpi.com/1420-3049/23/3/566

Similar Items

Binding Free Energy (BFE) Calculations and Quantitative Structure–Activity Relationship (QSAR) Analysis of <i>Schistosoma mansoni</i> Histone Deacetylase 8 (<i>sm</i>HDAC8) Inhibitors
by: Conrad V. Simoben, et al.
Published: (2021-04-01)

Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
by: Ehab Ghazy, et al.
Published: (2022-01-01)

Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni.
by: Martin Marek, et al.
Published: (2013-01-01)

Carbamates as Potential Prodrugs and a New Warhead for HDAC Inhibition
by: Kristina King, et al.
Published: (2018-02-01)

Docking, Binding Free Energy Calculations and In Vitro Characterization of Pyrazine Linked 2-Aminobenzamides as Novel Class I Histone Deacetylase (HDAC) Inhibitors
by: Emre F. Bülbül, et al.
Published: (2022-04-01)

Application of Ligand- and Structure-Based Prediction Models for the Design of Alkylhydrazide-Based HDAC3 Inhibitors as Novel Anti-Cancer Compounds
by: Emre F. Bülbül, et al.
Published: (2023-07-01)

Histone Deacetylase 6 (HDAC6) in Ciliopathies: Emerging Insights and Therapeutic Implications
by: Zhiyi Wang, et al.
Published: (2025-06-01)

The role of HDAC3 in inflammation: mechanisms and therapeutic implications
by: Noah Watson, et al.
Published: (2024-07-01)

Novel Histone Deacetylase (HDAC) Inhibitor Induces Apoptosis and Suppresses Invasion via E-Cadherin Upregulation in Pancreatic Ductal Adenocarcinoma (PDAC)
by: Katja Schiedlauske, et al.
Published: (2024-06-01)

Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
by: Elizabeth A. Thomas
Published: (2014-05-01)

Downregulation of histone deacetylase 8 (HDAC8) alleviated the progression of oral submucous fibrosis
by: Hui-Wen Yang, et al.
Published: (2023-04-01)

Novel selective indole based histone deacetylase 10 inhibitors as anticancer therapeutics
by: Amer H. Tarawneh, et al.
Published: (2025-09-01)

The Histone Deacetylase Family: Structural Features and Application of Combined Computational Methods
by: Antonio Curcio, et al.
Published: (2024-05-01)

Role of Histone Deacetylase 6 and Histone Deacetylase 6 Inhibition in Colorectal Cancer
by: Ana Vuletić, et al.
Published: (2023-12-01)

Development of novel benzamide class I selective lysine deacetylase inhibitors as potent anticancer agents
by: Jason H. Gill, et al.
Published: (2025-12-01)

Thermal shift engagement assay for Class IIA histone deacetylase inhibitor screening
by: Lauren N. Kotsull, et al.
Published: (2025-11-01)

Direct Amidation to Access 3-Amido-1,8-Naphthalimides Including Fluorescent Scriptaid Analogues as HDAC Inhibitors
by: Kyle N. Hearn, et al.
Published: (2021-06-01)

The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus
by: Saikat Dewanjee, et al.
Published: (2021-05-01)

HDAC6 inhibition disrupts HDAC6-P300 interaction reshaping the cancer chromatin landscape
by: Michela Gottardi Zamperla, et al.
Published: (2024-08-01)

Structure-Based Identification of Novel Histone Deacetylase 4 (HDAC4) Inhibitors
by: Rupesh Agarwal, et al.
Published: (2024-07-01)

Male histone deacetylase 6 (HDAC6) knockout mice have enhanced ventilatory responses to hypoxic challenge
by: Paulina M. Getsy, et al.
Published: (2024-02-01)

HDAC1 and HDAC2 Are Involved in Influenza A Virus-Induced Nuclear Translocation of Ectopically Expressed STAT3-GFP
by: Jessica Leong, et al.
Published: (2024-12-01)

Non-Hydroxamate Zinc-Binding Groups as Warheads for Histone Deacetylases
by: Anton Frühauf, et al.
Published: (2021-08-01)

HAT- and HDAC-Targeted Protein Acetylation in the Occurrence and Treatment of Epilepsy
by: Jie Wang, et al.
Published: (2022-12-01)

Tau-dependent HDAC1 nuclear reduction is associated with altered VGluT1 expression
by: Giacomo Siano, et al.
Published: (2023-05-01)

Experimental and Theoretical Investigation of the Coordination of 8-Hydroxquinoline Inhibitors to Biomimetic Zinc Complexes and Histone Deacetylase 8 (HDAC8)
by: Anthony M. Baudino, et al.
Published: (2024-08-01)

Histone deacetylases in hearing loss: Current perspectives for therapy
by: Daishi Chen, et al.
Published: (2017-06-01)

Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitors
by: Julia Krushkal, et al.
Published: (2024-12-01)

The Impact of Fluorination on the Design of Histone Deacetylase Inhibitors
by: Duong Tien Anh, et al.
Published: (2023-02-01)

Aberrant HDAC3 expression correlates with brain metastasis in breast cancer patients
by: Li Ma, et al.
Published: (2020-09-01)

HDAC Family Members Intertwined in the Regulation of Autophagy: A Druggable Vulnerability in Aggressive Tumor Entities
by: Emily Koeneke, et al.
Published: (2015-04-01)

Pathological Role of HDAC8: Cancer and Beyond
by: Ji Yoon Kim, et al.
Published: (2022-10-01)

HDAC10 and its implications in Sézary syndrome pathogenesis
by: Monika Pieniawska, et al.
Published: (2025-01-01)

Discovery of BRAF/HDAC Dual Inhibitors Suppressing Proliferation of Human Colorectal Cancer Cells
by: Yingjun Li, et al.
Published: (2022-07-01)

The identification of potent dual-target monopolar spindle 1 (MPS1) and histone deacetylase 8 (HDAC8) inhibitors through pharmacophore modeling, molecular docking, molecular dynamics simulations, and biological evaluation
by: Huilian Hua, et al.
Published: (2024-09-01)

Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention
by: Dusan Ruzic, et al.
Published: (2022-01-01)

Genome-Wide Identification and Characterization of the <i>Salvia miltiorrhiza</i> Histone Deacetylase (HDAC) Family in Response to Multiple Abiotic Stresses
by: Junyu Chen, et al.
Published: (2024-02-01)

Targeting histone deacetylase 6 mediates a dual anti‐melanoma effect: Enhanced antitumor immunity and impaired cell proliferation
by: K.V. Woan, et al.
Published: (2015-08-01)

Histone deacetylases: potential therapeutic targets for idiopathic pulmonary fibrosis
by: Hai-peng Cheng, et al.
Published: (2024-08-01)

The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors
by: Fangyuan Cao, et al.
Published: (2018-03-01)